Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial.

Author: AlbaredaNuria, AlonsoFernando García, HebertAdelaide A, RosenTheodore, RosenbergNoah, RothSandra, ZsoltIlonka

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Topical ozenoxacin is effective and well tolerated in the treatment of impetigo in patients 2 months and older. It was found to be superior to placebo in both clinical and microbiological success. Topical ozenoxacin represents a novel option for the treatment of impetigo.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Ozenoxacin, a novel topical antibacterial agent with potent bactericidal activity against gram-positive bacteria, has been developed as a cream with 1% active drug for the treatment of impetigo, a highly contagious bacterial skin infection. OBJECTIVES: To evaluate the efficacy, safety, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128489/

データ提供：米国国立医学図書館（NLM）

A New Weapon in the Fight Against Impetigo

Impetigo is a highly contagious bacterial skin infection that often affects children. This research evaluates the effectiveness and safety of [ozenoxacin cream] as a treatment for impetigo. The authors conducted a [randomized controlled clinical trial] to compare the efficacy of ozenoxacin to a placebo. They discovered that ozenoxacin cream was significantly more effective in clearing the infection than the placebo. This study adds to the arsenal of treatments for impetigo, offering a new option for both adults and children.

Ozenoxacin Cream: A Promising New Treatment for Impetigo

The research demonstrates the effectiveness of ozenoxacin cream in treating impetigo, especially in comparison to a placebo. This finding is significant as it provides healthcare providers with a new treatment option for this common and often troublesome skin infection. This research is like a refreshing oasis in the desert of impetigo, offering a new hope for rapid and effective treatment.

Keeping Impetigo at Bay

Impetigo can be a pesky problem, but the research offers a new weapon in the fight against this skin infection. Ozenoxacin cream, a topical antibacterial agent, has shown promising results in clinical trials, providing a valuable tool for treating impetigo and preventing its spread. By taking a proactive approach to skin health and seeking prompt treatment when necessary, we can keep impetigo at bay and maintain clear and healthy skin.

Dr.Camel's Conclusion

This study provides valuable insights into the effectiveness and safety of ozenoxacin cream as a treatment for impetigo, offering a new and promising option for both adults and children. It's a beacon of hope in the desert of skin infections, providing a much-needed solution to a common problem. This research is a testament to the ongoing pursuit of innovative treatments for a wide range of health conditions.

Date :
  1. Date Completed 2019-09-16
  2. Date Revised 2019-09-16
Further Info :

Pubmed ID

29898217

DOI: Digital Object Identifier

PMC6128489

Related Literature

Article Analysis
・Effects of ozenoxacin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.